📰 Targeted Augmentation News
Page 5 - Targeted Augmentation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Targeted Augmentation. Real-time updates on events, politics, business and more.
January 20, 2022
Most Dravet syndrome epilepsy cases are caused by a mutation in the SCN1A gene, resulting in a reduction in SCN1A protein production. A novel therapeutic approach, called TANGO, is designed to boost production of SCN1A to normal levels. If successful, it would be the first treatment for the fundamental cause of the disease, a lack of this particular protein in specialized brain cells.
January 20, 2022
Research from the University of Virginia School of Medicine suggests how a newly developed gene therapy can treat Dravet syndrome, a severe form of epilepsy, and potentially prolong survival for people with the condition.
January 19, 2022
Research from the University of Virginia School of Medicine suggests how a gene therapy can treat Dravet syndrome, a severe form of epilepsy.
December 3, 2021
– Single doses of STK-001 up to 30mg and multiple doses of 20mg were well tolerated with no safety concerns related to study drug – – 70.6% of patients treated with STK-001... | December 3, 2021
November 3, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation.
May 10, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation. Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates May 10, 2021 GMT BEDFORD, Mass.--(BUSINESS WIRE)--May 10, 2021-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 20...
March 10, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation. Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates March 9, 2021 GMT BEDFORD, Mass.--(BUSINESS WIRE)--Mar 9, 2021-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial results for the full year ended De...